GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharmosa Biopharm 6875.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

25.30

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 67.3m

FY2018FY2025

Net income

−TWD 383.8m

FY2018FY2025

Free cash flow

−TWD 476.8m

FY2018FY2025

Shareholders' equity

TWD 1.56bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueTWD 67.3mTWD 167.6mTWD 314.5m—————
Gross profitTWD 13.0mTWD 126.9mTWD 314.5m—————
Research and developmentTWD 366.7mTWD 294.8mTWD 277.0mTWD 242.3mTWD 240.8mTWD 175.3mTWD 129.0mTWD 72.2m
Operating income−TWD 402.9m−TWD 218.6mTWD 11.3m−TWD 265.9m−TWD 255.3m−TWD 177.8m−TWD 139.1m−TWD 81.9m
Net income−TWD 383.8m−TWD 166.7mTWD 8.5m−TWD 266.5m−TWD 256.5m−TWD 181.7m−TWD 129.6m−TWD 79.7m
Diluted earnings per share-2.97-1.280.07-2.65-2.94-3.72-1.29-0.79

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsTWD 1.75bnTWD 2.16bnTWD 1.33bnTWD 799.4mTWD 586.4mTWD 543.3m—TWD 115.8m
Cash and short-term investments——TWD 974.1mTWD 672.5mTWD 461.5mTWD 414.5mTWD 84.9mTWD 18.2m
Total liabilitiesTWD 190.6mTWD 225.7mTWD 196.0mTWD 38.2mTWD 54.9mTWD 137.4m—TWD 86.7m
Debt—TWD 117.6mTWD 144.4mTWD 21.2mTWD 37.1mTWD 105.6mTWD 125.6mTWD 72.0m
Shareholders' equityTWD 1.56bnTWD 1.94bnTWD 1.14bnTWD 761.1mTWD 531.4mTWD 405.8m—TWD 29.1m
Shares outstanding129m130m117m101m87m49m101m101m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−TWD 357.5m−TWD 127.2mTWD 42.4m−TWD 258.3m−TWD 237.5m−TWD 181.4m—−TWD 74.1m
Capital spending−TWD 119.3m−TWD 166.0m−TWD 81.5m−TWD 10.2m−TWD 3.2m−TWD 7.1m—−TWD 1.6m
Free cash flow−TWD 476.8m−TWD 293.1m−TWD 39.0m−TWD 268.5m−TWD 240.8m−TWD 188.5m—−TWD 75.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—TWD 1.8mTWD 47.6mTWD 4.0mTWD 15.7m—TWD 117.0mTWD 40.9m
Gross profit—TWD 330,000TWD 9.6mTWD 667,000TWD 2.8m—TWD 113.5mTWD 10.7m
Operating income−TWD 101.9m−TWD 103.2m−TWD 131.5m−TWD 70.1m−TWD 90.6m−TWD 110.6mTWD 14.3m−TWD 92.1m
Net income−TWD 100.1m−TWD 94.2m−TWD 111.2m−TWD 45.9m−TWD 133.9m−TWD 92.9mTWD 34.9m−TWD 90.1m
Diluted earnings per share-0.78-0.73-0.86-0.36-1.04-0.720.27-0.69
Cash from operations−TWD 57.0m−TWD 138.0m−TWD 67.0m−TWD 55.0m−TWD 140.0m−TWD 93.0mTWD 70.0m−TWD 94.0m
Capital spending−TWD 22.0m−TWD 118.0m−TWD 14.0m−TWD 24.0m—−TWD 80.0m−TWD 56.0m−TWD 39.0m
Free cash flow−TWD 79.0m−TWD 256.0m−TWD 81.0m−TWD 79.0m—−TWD 173.0mTWD 14.0m−TWD 133.0m
Total assetsTWD 1.78bnTWD 1.62bnTWD 1.75bnTWD 1.86bnTWD 1.91bnTWD 2.07bnTWD 2.16bnTWD 2.08bn
DebtTWD 150.0m———————
Shareholders' equityTWD 1.37bnTWD 1.47bnTWD 1.56bnTWD 1.67bnTWD 1.71bnTWD 1.85bnTWD 1.94bnTWD 1.90bn

Financial ratios

Data as of 15 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin19.4%75.7%100.0%———
Operating margin-567.5%-98.0%3.6%———
Net margin-570.6%-99.5%2.7%———
Return on equity-24.6%-8.6%0.7%-35.0%-48.3%-44.8%
Return on assets-22.0%-7.7%0.6%-33.3%-43.7%-33.4%
Free cash flow yield—1.1%4.0%-9.3%——
Revenue growth-59.9%-46.7%————
Earnings growth130.3%-2070.8%-103.2%3.9%41.2%—
Current ratio12.11x14.48x13.02x24.65x14.39x4.31x
Debt to equity—0.00x0.02x0.02x0.04x0.21x
Equity ratio89.1%89.6%85.3%95.2%90.6%74.7%
Interest coverage-181.79x-67.89x3.96x-409.64x-210.27x-46.08x
R&D as a share of sales545.1%175.9%88.1%———
Buybacks as a share of market value—-11.1%-16.6%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income14.9%17.8%—
Net income12.9%16.1%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin59.6%———
Operating margin-264.6%———
Net margin-234.4%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-17.4-41.3—-23.4
Price to sales99.641.132.8—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.